RecallDepth
Class I Terminated

IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single Dose Vial, Rx Only, Teva Pharmaceuticals, USA, Inc., North Wales, PA 19454, NDC 0703-4154-11.

Company
Teva Pharmaceuticals Usa, Inc
Recall Initiated
March 29, 2022
Posted
April 20, 2022
Recall Number
D-0765-2022
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
1565 vials
Firm Location
Parsippany, NJ, United States

Reason for Recall

Presence of Particulate Matter: Product was found to contain silica and iron oxide

Distribution

Nationwide within the United States

Lot / Code Info

Lot #: 31329657B, Exp. Date 08/2023

More recalls by Teva Pharmaceuticals Usa, Inc

View all recalls by this company →

Other recent Class I Drug recalls